Sanofi, Merrimack cancer drug flops (again) in second round of PhII program

John Carroll Seven months after a mid-stage cancer drug from Sanofi and Merrimack Pharmaceuticals flunked its first mid-stage test, researchers are back with another failure to report. ...

Vaccine plant problems put Sanofi shot supplies in dire straits

Tracy Staton Last year, the FDA came down hard on a Sanofi Pasteur plant in Toronto. The ensuing trouble triggered serious supply problems–and, in turn, a shortage of childhood ...

Sanofi, Glaxo sign up for vaccine R&D projects under new Gates initiative

John Carroll In its joint venture, Glaxo will front $ 1.8 million for work on the thermostability of vaccines. GSK will set out to make adjuvants–used to boost the effectiveness ...

Sanofi nabs OTC nod for Nasacort amid consumer healthcare push

Carly Helfand It's a win for the company, whose consumer healthcare strategy focuses on switching drugs over from prescription status. And it sets a regulatory precedent for other ...

Sanofi plots more cuts at slow-footed French R&D shop

Damian Garde Long bedeviled by union protests and government chidings, Sanofi is again planning to pare down its French R&D operation, plotting 186 job cuts as worker groups mobilize ...

Ex-Celgene, Sanofi execs plead guilty on insider trading charges

John Carroll Some old high school buddies who went on to profit from insider information on deals at Celgene and Sanofi are now facing sentencing after pleading guilty to securities ...

Novartis, Sanofi, Biogen tout new MS drug research

Tracy Staton New data is rolling out at the European Committee for Treatment and Research in Multiple Sclerosis annual meeting this week, with the new slate of oral treatments in the ...

Sanofi chief: Emerging markets are worth the hassle

Tracy Staton On the path into emerging markets, drugmakers have stumbled across a thorny regulatory bush here, a pricing sinkhole there–not to mention a couple of big bad wolves ...

Great expectations build for PCSK9 blockbuster prospect from Sanofi, Regeneron

John Carroll In an industry like pharma, you're only as good as your next big Phase III study. And hopes are running very, very high for the first round of late-stage results on ...

Sanofi and Aviesan Renew French Agreement

mia.burns Sanofi and Aviesan Renew their Agreement to Accelerate Research in France -Three-year renewal of the cooperation protocol- Paris, France-September 27, 2013- Sanofi (EURONEXT: ...

Sanofi Pays $40M To Settle Suit About Fibs And Its Failed Fat Pill

esilverman Six years after Sanofi withdrew its application to sell its troubled Acomplia diet pill in the US over concerns about psychiatric side effects, the drugmaker has ...

Sanofi rids itself of Zimulti suit, but its legacy weighs on new-generation obesity pills

Eric Palmer When the FDA approved two new obesity drugs last year, there was some surprise because of the ugly regulatory and legal entanglements of weight-loss drugs that preceded ...
Page 5 of 10« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS